---
$id: https://graph.org.ai/products/commodity/51111641
$type: Product
source: UNSPSC
code: "51111641"
title: "Galocitabine"
class: "51111600"
classTitle: "Antimetabolites"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Galocitabine

**UNSPSC Code**: 51111641
**Class**: [Antimetabolites](Antimetabolites.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a pyrimidine antagonist with the molecular formula C19H22FN3O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X9788XI79O, chemically known as 5-deoxy-5-fluoro-n-(3,4,5-trimethoxybenzoyl)cytidine but generally known as galocitabine, which bears US NIH Compound Identifier 65950. European Medicines Agency schedules Galocitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07875MIG. The term GALOCITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). GALOCITABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule galocitabine under HS 29349990 and SITC 51579. As of Q4 2014, GALOCITABINE remains the US FDA Preferred Term for this commodity. Galocitabine bears US NLM identifiers UMLS ID C0084382 and NCI Concept Code C73254. SMILES: FC1CN(C2OC(C(O)C2O)C)C(=O)NC1NC(=O)C1CC(OC)C(OC)C(OC)C1.

